MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials¹ ...
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6 Approval ...
Health doesn't only begin in hospitals and clinics. It can often start wherever people gather and trust one another. That's why Novartis and the Novartis Foundation work alongside local partners to ...
Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only.
Afrique du Sud Albanie Algérie Allemagne Ancienne république yougoslave de Macédoine Argentine Arménie Australie Autriche Bahamas Barbade Belgique Bénin Bermudes Bolivie Bosnie-Herzégovine Brésil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results